NCT06250283

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: University of Delaware · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Detailed description

We plan to enroll and screen 68 women, with an estimated 34 qualifying women will be randomly assigned to two groups: 1) the placebo group and 2) the resveratrol group. The resveratrol group will receive 500 mg resveratrol daily for 24 weeks, and placebo group will receive placebo pills. Both groups will receive 500 mg calcium plus 400 IU vitamin D daily. Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks.

Conditions

• Low Bone Mass

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Resveratrol	Resveratrol (500 mg)
DIETARY_SUPPLEMENT	Placebo	Placebo (500 mg)

Timeline

• Start date: 2024-02-02
• Primary completion: 2025-10-30
• Completion: 2026-01-30
• First posted: 2024-02-09
• Last updated: 2026-03-10

Locations

1 site across 1 country: United States